Related Experiment Video
Updated: May 10, 2026
05:18
Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure
Published on: January 16, 2026
Cost-effectiveness of continuous-flow left ventricular assist devices
Mattias Neyt1, Ann Van den Bruel, Yolba Smit
1ME-TA, Medical Evaluation and Technology Assessment, Belgium. mattias.neyt@me-ta.eu
Summary
Continuous-flow left ventricular assist devices (LVADs) significantly increase life-years and quality-adjusted life-years for end-stage heart failure patients. However, the high cost of LVAD therapy raises questions about its reimbursement.
Area of Science:
- Cardiology
- Health Economics
- Medical Technology Assessment
Background:
- Left ventricular assist devices (LVADs) offer improved survival and quality of life for patients with end-stage heart failure.
- Continuous-flow LVADs represent an advancement in mechanical circulatory support for patients ineligible for heart transplantation.
Purpose of the Study:
- To determine the cost-effectiveness of continuous-flow LVADs compared to optimal medical therapy (OMT).
- To evaluate the economic value of LVAD destination therapy from a societal perspective.
Main Methods:
- A lifetime Markov model was utilized for cost-utility analysis.
- Treatment effects were indirectly modeled by combining data from key clinical trials.
- Cost data were derived from real-world financial records of LVAD recipients.
Main Results:
- Continuous-flow LVADs yielded an average gain of 3.23 life-years or 2.83 quality-adjusted life-years per patient.
- The incremental cost-effectiveness ratio was €94,100 per life-year gained and €107,600 per quality-adjusted life-year gained.
- Sensitivity analyses confirmed the robustness of these cost-effectiveness findings.
Conclusions:
- LVAD destination therapy enhances patient survival and quality of life.
- Despite clinical benefits, LVADs are a costly intervention, prompting considerations regarding reimbursement policies.
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.